You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Multi-day Pain Management Therapy with Novel Injectable Formulation

    SBC: ORBIS BIOSCIENCES, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Our long term goal is to widespread the use of PPF technology for promoting effective production of drug-encapsulating microparticles with uniform size and physical characteristics that can be leveraged to release a specific drug at controlled rates over multi-day periods in vivo after a single administration. For this proposal, we are specifically targeting a ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. Anti-CD47 mAb Therapy to Improve Kidney Transplantation

    SBC: VASCULOX, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die while waitlisted for organs. While there have been manyrecent strides in organ procurement, preservation and follow-up immune suppression, prevention of ischemia-reperfusion injury (IRI) remains prob ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Nanocomposite Imaging System for the Eye

    SBC: KYPHA INC.            Topic: NEI

    DESCRIPTION (provided by applicant): The purpose of this SBIR project is to develop a new dual-modality inflammation imaging technology to early detect Uveitis, an ocular inflammation-related disorder. This technology, based on nanocomposites (NCs) that function as dual-modality fluorescent and acoustic contrast agents for optical and ultrasound imaging techniques, will allow both quantitative ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Controlled Release of Topical Nitric Oxide for Treating Cutaneous Injuries

    SBC: SARMONT, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Nitric oxide (NO) has been shown to have powerful, broad-spectrum antimicrobial activity as well as benefits in wound healing when properly administered [1-3]. The combination of these two attributes makes development of a non-systemic NO delivery approach valuable for hospital and outpatient applications to prevent infection and accelerate wound healing. Such ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Enhanced system for atrial defibrillation

    SBC: CARDIALEN, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most prevalent clinical arrhythmia in clinical practice and a major contributor to morbidity and mortality. A recent study estimated that the number of Americans afflicted by AF will increase from the current range of 2.2 to 5.6 million to more than 12 million by 2050. This increase will be driven significantly by demographics, s ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a prototype system for assaying exocytosis from individual cells

    SBC: EXOCYTRONICS, LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): Cells secrete hormones and neurotransmitter via exocytosis. Understanding how exocytosis is regulated and how pharmaceuticals and toxins inhibit exocytosis is of broad medical significance. The overall goal of this SBIRproject is to use microfabrication technology to develop a robust and easy-to-use prototype device that can assay release of transmitter from in ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Improved long-term biocompatibility of coronary stents by plasma coating process

    SBC: NANOVA INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Improved long-term biocompatibility of coronary stents by plasma coating process Abstract Drug-eluting stents (DES) have been widely used to treat patients of cardiac disease due to their better ability to control restenosis than bare metal stents (BMS). However, a serious adverse outcome of late stent thrombosis in patients treated with DES has been reported, ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Measuring metabolism of C-terminal fragments of amyloid beta in the human central

    SBC: C2N DIAGNOSTICS LLC            Topic: NIA

    DESCRIPTION (provided by applicant): This grant will seek to develop a methodology that will allow us to test whether a promising new class of drugs for Alzheimer's disease is having the desired effect in the human brain. This methodology will allow pharmaceutical companies to make informed decisions about which drugs to advance into late stage clinical trials, and to optimize dosing and admi ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  9. SBIR TOPIC 294 PHASE 1- DEVELOPMENT OF GLYCOSYLATION- SPECIFIC RESEARCH

    SBC: MEDIOMICS, LLC            Topic: NCI

    Glycosylation changes are a universal feature of malignant transformation and tumor progression. Changes in expression levels of certain glycoproteins and altered glycosylation patterns have been detected in most of the major human cancer types and at different stages of tumor progression. The early detection of glycosylation changes is therefore crucial for cancer diagnosis and treatment. Curr ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. TAS::75 0849::TAS TOPIC 255: A NOVEL, NON-COMPETITIVE ANDROGEN RECEPTOR INHIBITOR

    SBC: ARTA BIOSCIENCE, INC.            Topic: NCI

    The androgen receptor (AR) remains a key therapeutic target for prostate cancer (PCa), even in castration resistant PCa (CRPC). Current therapies target AR by blocking androgen synthesis or competitive antagonism. ARTA Bioscience is developing an early lead, ABS-001, a non-competitive AR inhibitor that is synergistic with competitive antagonists. It blocks ligand-induced conformational change i ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government